Molecular testing has become a mandatory component of the non-small cell lung cancer
(NSCLC) management. The detection of EGFR, BRAF and MET mutations as well as the …

Lung cancer still contributes to nearly one‐quarter cancer‐related deaths in the past
decades, despite the rapid development of targeted therapy and immunotherapy in non …

Background For locally advanced rectal cancer (LARC) patients who receive neoadjuvant
chemoradiotherapy (nCRT), there are no reliable indicators to accurately predict …

Purpose Immunotherapy is regarded as the most promising treatment for cancer. However,
immune checkpoint inhibitors (ICIs) are not effective for all patients. Herein, we conducted a …

Background Treatment of oncogene-addicted non-small cell lung cancer (NSCLC) has been
changed by the advent of tyrosine kinase inhibitors (TKIs). Albeit great benefits are achieved …

Background With the identification of new targetable drivers and the recent emergence of
novel targeted drugs, using comprehensive genomic profiling in lieu of the routine testing for …

Background. Nonsmall cell lung cancer (NSCLC) is the most common type of lung cancer,
and the majority of NSCLC patients are diagnosed at the advanced stage. Chemotherapy is …

Over the past few years, immune checkpoint inhibitors (ICIs) have greatly improved the
survival for patients with non‐small cell lung cancer (NSCLC) without driver mutations …

Background The genomic mutation and immune feature landscape of ERBB2 exon 20
insertion (ERBB2-ex20ins)-driven non-small cell lung cancer and the features associated …

Breast cancer (BRCA) has traditionally been considered as having poor immunogenicity
and is characterized by relatively low tumor mutational burden (TMB). Improving …